tiprankstipranks
Madrigal Pharmaceuticals Inc (CH:YDO1)
:YDO1
Switzerland Market
YDO1
Madrigal Pharmaceuticals
RESEARCH TOOLSreports

Madrigal Pharmaceuticals (YDO1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

YDO1 Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Madrigal
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

YDO1 Stock 12 Month Forecast

Average Price Target

―
Based on 13 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is CHF559.42 with a high forecast of CHF781.00 and a low forecast of CHF440.83. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF781.00Average Price TargetCHF559.42Lowest Price TargetCHF440.83
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:YDO1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF496.85
Buy
―
Reiterated
08/11/26
Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
Wolfe Research Analyst forecast on CH:YDO1
Andy Chen
Wolfe Research
Wolfe Research
CHF491.17
Buy
―
Upgraded
08/04/26
Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research
Barclays Analyst forecast on CH:YDO1
Eliana Merle
Barclays
Barclays
CHF782.62→CHF781
Buy
―
Reiterated
08/03/26
Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
B. Riley Securities Analyst forecast on CH:YDO1
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
CHF543.94
Buy
―
Initiated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities
Truist Financial Analyst forecast on CH:YDO1
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF575.6
Buy
―
Reiterated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on CH:YDO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF503.34
Buy
―
Reiterated
07/31/26
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
TD Cowen Analyst forecast on CH:YDO1
Ritu Baral
TD Cowen
TD Cowen
CHF522.83
Buy
―
Reiterated
07/30/26
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Bank of America Securities Analyst forecast on CH:YDO1
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF448.95→CHF440.83
Hold
―
Reiterated
07/30/26
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
Wells Fargo Analyst forecast on CH:YDO1
Sadia Rahman
Wells Fargo
Wells Fargo
CHF556.11
Buy
―
Initiated
07/27/26
Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
UBS Analyst forecast on CH:YDO1
Ashwani Verma
UBS
UBS
CHF543.12
Buy
―
Reiterated
07/21/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS
Citizens JMP Analyst forecast on CH:YDO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF598.33→CHF599.95
Buy
―
Reiterated
07/17/26
Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
Jefferies Analyst forecast on CH:YDO1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF487.11
Buy
―
Reiterated
06/30/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on CH:YDO1
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF730.66
Buy
―
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Evercore ISI Analyst forecast on CH:YDO1
Michael DiFiore
Evercore ISI
Evercore ISI
CHF529.32→CHF526.89
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Clear Street Analyst forecast on CH:YDO1
Kaveri Pohlman
Clear Street
Clear Street
CHF432.71→CHF552.05
Buy
―
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:YDO1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF496.85
Buy
―
Reiterated
08/11/26
Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
Wolfe Research Analyst forecast on CH:YDO1
Andy Chen
Wolfe Research
Wolfe Research
CHF491.17
Buy
―
Upgraded
08/04/26
Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research
Barclays Analyst forecast on CH:YDO1
Eliana Merle
Barclays
Barclays
CHF782.62→CHF781
Buy
―
Reiterated
08/03/26
Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
B. Riley Securities Analyst forecast on CH:YDO1
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
CHF543.94
Buy
―
Initiated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities
Truist Financial Analyst forecast on CH:YDO1
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF575.6
Buy
―
Reiterated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on CH:YDO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF503.34
Buy
―
Reiterated
07/31/26
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
TD Cowen Analyst forecast on CH:YDO1
Ritu Baral
TD Cowen
TD Cowen
CHF522.83
Buy
―
Reiterated
07/30/26
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Bank of America Securities Analyst forecast on CH:YDO1
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF448.95→CHF440.83
Hold
―
Reiterated
07/30/26
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
Wells Fargo Analyst forecast on CH:YDO1
Sadia Rahman
Wells Fargo
Wells Fargo
CHF556.11
Buy
―
Initiated
07/27/26
Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
UBS Analyst forecast on CH:YDO1
Ashwani Verma
UBS
UBS
CHF543.12
Buy
―
Reiterated
07/21/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS
Citizens JMP Analyst forecast on CH:YDO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF598.33→CHF599.95
Buy
―
Reiterated
07/17/26
Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
Jefferies Analyst forecast on CH:YDO1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF487.11
Buy
―
Reiterated
06/30/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on CH:YDO1
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF730.66
Buy
―
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Evercore ISI Analyst forecast on CH:YDO1
Michael DiFiore
Evercore ISI
Evercore ISI
CHF529.32→CHF526.89
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Clear Street Analyst forecast on CH:YDO1
Kaveri Pohlman
Clear Street
Clear Street
CHF432.71→CHF552.05
Buy
―
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

3 Months
Thomas SmithLeerink Partners
Success Rate
15/21 ratings generated profit
71%
Average Return
+25.86%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +25.86% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
28/34 ratings generated profit
82%
Average Return
+45.06%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +45.06% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
20/21 ratings generated profit
95%
Average Return
+101.88%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +101.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

YDO1 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
2
4
5
5
Buy
8
11
11
19
12
Hold
4
2
3
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
15
18
29
21
In the current month, YDO1 has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. YDO1 average Analyst price target in the past 3 months is 559.42.
Each month's total comprises the sum of three months' worth of ratings.

YDO1 Financial Forecast

YDO1 Earnings Forecast

Next quarter’s earnings estimate for YDO1 is -CHF0.70 with a range of -CHF1.62 to -CHF0.08. The previous quarter’s EPS was -CHF1.61. YDO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for YDO1 is -CHF0.70 with a range of -CHF1.62 to -CHF0.08. The previous quarter’s EPS was -CHF1.61. YDO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Sales Forecast

Next quarter’s sales forecast for YDO1 is CHF326.89M with a range of CHF311.13M to CHF343.72M. The previous quarter’s sales results were CHF294.59M. YDO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.
Next quarter’s sales forecast for YDO1 is CHF326.89M with a range of CHF311.13M to CHF343.72M. The previous quarter’s sales results were CHF294.59M. YDO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Stock Forecast FAQ

What is CH:YDO1’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 559.42.
    What is CH:YDO1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:YDO1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Madrigal Pharmaceuticals Inc a Buy, Sell or Hold?
        Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Madrigal Pharmaceuticals Inc’s share price target?
          The average share price target for Madrigal Pharmaceuticals Inc is 559.42. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF781.00 ,and the lowest forecast is CHF440.83. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Madrigal Pharmaceuticals Inc?
            Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Madrigal Pharmaceuticals Inc?
              To buy shares of CH:YDO1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.